Table: q1_q4_2023_prescription_drug_wac_increases , manufacturer_name like I*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id manufacturer_name date_reported ndc_number drug_product_description drug_category drug_category_source wac_effective_date wac_increase_amount wac_after_increase patent_expiration_date drug_source_type unit_sales_volume_in_us unit_sales_volume_non_public_indicator cost_increase_factors cost_increase_factors_non_public_indicator change_improvement_description change_improvement_non_public_indicator acquisition_date company_acquired_from acquisition_price acquisition_price_non_public_indicator acquisition_price_comment wac_at_acquisition wac_year_prior_to_acquisition year_drug_introduced_to_market wac_at_intro_to_market supporting_documents general_comments
Rx0000160 Incyte Corporation 03/31/2023 50881001060 Jakafi Oral Tablet 10 mg 60 Pack Brand FDA 01/09/2023 486.00 16686.00 12/12/2028 Single Source Drug None 1 Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. None None 1 None None None None None None None None None None None
Rx0000160 Incyte Corporation 12/31/2023 50881001060 Jakafi Oral Tablet 10 mg 60 Pack Brand FDA 10/01/2023 334.00 17020.00 12/12/2028 Single Source Drug None 1 Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. None None 1 None None None None None None None None None None None
Rx0000160 Incyte Corporation 03/31/2023 50881001560 Jakafi Oral Tablet 15 mg 60 Pack Brand FDA 01/09/2023 486.00 16686.00 12/12/2028 Single Source Drug None 1 Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. None None 1 None None None None None None None None None None None
Rx0000160 Incyte Corporation 12/31/2023 50881001560 Jakafi Oral Tablet 15 mg 60 Pack Brand FDA 10/01/2023 334.00 17020.00 12/12/2028 Single Source Drug None 1 Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. None None 1 None None None None None None None None None None None
Rx0000160 Incyte Corporation 03/31/2023 50881002060 Jakafi Oral Tablet 20 mg 60 Pack Brand FDA 01/09/2023 486.00 16686.00 12/12/2028 Single Source Drug None 1 Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. None None 1 None None None None None None None None None None None
Rx0000160 Incyte Corporation 12/31/2023 50881002060 Jakafi Oral Tablet 20 mg 60 Pack Brand FDA 10/01/2023 334.00 17020.00 12/12/2028 Single Source Drug None 1 Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. None None 1 None None None None None None None None None None None
Rx0000160 Incyte Corporation 03/31/2023 50881002560 Jakafi Oral Tablet 25 mg 60 Pack Brand FDA 01/09/2023 486.00 16686.00 12/12/2028 Single Source Drug None 1 Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. None None 1 None None None None None None None None None None None
Rx0000160 Incyte Corporation 12/31/2023 50881002560 Jakafi Oral Tablet 25 mg 60 Pack Brand FDA 10/01/2023 334.00 17020.00 12/12/2028 Single Source Drug None 1 Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. None None 1 None None None None None None None None None None None
Rx0000160 Incyte Corporation 03/31/2023 50881000560 Jakafi Oral Tablet 5 mg 60 Pack Brand FDA 01/09/2023 486.00 16686.00 12/12/2028 Single Source Drug None 1 Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. None None 1 None None None None None None None None None None None
Rx0000160 Incyte Corporation 12/31/2023 50881000560 Jakafi Oral Tablet 5 mg 60 Pack Brand FDA 10/01/2023 334.00 17020.00 12/12/2028 Single Source Drug None 1 Incyte is driven by rigorous science and our pricing decisions allow us to invest in scientific advancements in areas of high unmet medical need. Incyte responsibly prices our medicines and makes price revisions with consideration to market conditions, patient access, and the clinical value that our medicines deliver to patients. None None 1 None None None None None None None None None None None
Rx0000040 Ingenus Pharmaceuticals, LLC 09/30/2023 50742044745 Carboplatin Injection 450mg, 45ml Generic FDA 08/20/2023 33.27 75.00 None Non-innovator Multiple Source Drug 120000 None Carboplatin 450mg/45mL and 600mg/60mL (ANDA 208487) has been priced in accordance with Ingenus Pharmaceuticals Contracts and Management Team policies and procedures. Establishing the WAC price at $75.00 and $100.00 constitutes a reasonable WAC price as we reenter the market after previously exiting due to competitive reasons. Our pricing analysis has been complete, our new WAC should help us compete in a market in which we were previously unable to. Several factors were taken into consideration while determining Ingenus’ WAC pricing including but limited to API, production, packaging, and shipping costs. Ingenus’ WAC pricing will enable it to: i) recoup the costs it incurred in evaluating the economic landscape surrounding prospective products; ii) cover distribution costs; iii) provide rebates and discounts as required by partners in the supply chain; and iv) earn a reasonable return on investment. None There was no change or improvement to the drug. None None None None None None None None None None None None
Rx0000040 Ingenus Pharmaceuticals, LLC 09/30/2023 50742044860 Carboplatin Injection 600mg, 60ml Generic FDA 08/20/2023 48.29 100.00 None Non-innovator Multiple Source Drug 65000 None Carboplatin 450mg/45mL and 600mg/60mL (ANDA 208487) has been priced in accordance with Ingenus Pharmaceuticals Contracts and Management Team policies and procedures. Establishing the WAC price at $75.00 and $100.00 constitutes a reasonable WAC price as we reenter the market after previously exiting due to competitive reasons. Our pricing analysis has been complete, our new WAC should help us compete in a market in which we were previously unable to. Several factors were taken into consideration while determining Ingenus’ WAC pricing including but limited to API, production, packaging, and shipping costs. Ingenus’ WAC pricing will enable it to: i) recoup the costs it incurred in evaluating the economic landscape surrounding prospective products; ii) cover distribution costs; iii) provide rebates and discounts as required by partners in the supply chain; and iv) earn a reasonable return on investment. None There was no change or improvement to the drug. None None None None None None None None None None None None
Rx0000287 Insmed Incorporated 03/31/2023 71558059028 Arikayce Inhalation Suspension 590 MG/8.4ML Package Size 8.4 ML Package Quantity/Vial Quantity 28 Brand FDA 01/01/2023 1069.78 14441.99 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000266 Intercept Pharmaceuticals, Inc. 09/30/2023 69516001030 Ocaliva Oral Tablet 10mg 30 count in 1 bottle Brand FDA 08/01/2023 502.63 9021.77 04/26/2036 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000266 Intercept Pharmaceuticals, Inc. 09/30/2023 69516000530 Ocaliva Oral Tablet 5mg 30 count in 1 bottle Brand FDA 08/01/2023 502.63 9021.77 04/26/2036 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000266 Intercept Pharmaceuticals, Inc. 03/31/2023 69516001030 Ocaliva® (obeticholic acid) tablets 10mg, 30 Count Bottle Brand FDA 01/19/2023 474.63 8519.14 04/26/2036 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None This is a revision to the previously filed increase notice and report.
Rx0000266 Intercept Pharmaceuticals, Inc. 03/31/2023 69516000530 Ocaliva® (obeticholic acid) tablets 5mg 30 Count Bottle Brand FDA 01/19/2023 474.63 8519.14 04/26/2036 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None This is a revision to the previously filed increase notice and report.
Rx0000214 Intra-Cellular Therapies, Inc. 06/30/2023 72060014230 Caplyta Oral Capsule 42 MG 30 Pack Brand FDA 05/29/2023 87.42 1569.17 None Single Source Drug None 1 None 1 None 1 None None None None None None None None None None None
Rx0000084 Ipsen Biopharmaceuticals, Inc. 03/31/2023 15054104005 Drug product name: Increlex. Drug product strength: 10 mg/ml. Drug product dosage form: vial. Drug product package size: 1 vial (4ml). Brand FDA 01/01/2023 253.00 5882.00 03/11/2033 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The product was not acquired by Ipsen within the previous five years.
Rx0000084 Ipsen Biopharmaceuticals, Inc. 12/31/2023 15054004301 Drug product name: Onivyde. Drug product strength: 43 mg/10 ml (4.3 mg/ml). Drug product dosage form: vial. Drug product package size: 10ml. Brand FDA 10/01/2023 67.00 2766.00 10/15/2036 Single Source Drug None 1 None 1 None 1 None None None None None None None None None None The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book. The information provided in response to 22 CCR § 96070(b)(11) contains price increases for the drug product when the NDC for the product was 69171-0398-01
Rx0000084 Ipsen Biopharmaceuticals, Inc. 03/31/2023 72607010000 Drug product name: Tazverik. Drug product strength: 200mg. Drug product dosage form: tablet. Drug product package size: 1 bottle (240 tablets). Brand FDA 02/15/2023 1104.00 18850.00 12/19/2035 Single Source Drug None 1 None 1 None 1 08/12/2022 Epizyme, Inc. None None For purposes of 22 CCR § 96070(b)(12)(c) (requirement to report the purchase price of the relevant drug, if the drug was acquired by the manufacturer within the previous five years), Ipsen purchased Epizyme, Inc. in August 2022, including Tazverik. The purchase price of the drug product (as Ipsen understands that data element) is not in the public domain or otherwise publicly available. However, information regarding Ipsen’s purchase of Epizyme, Inc. is available on p. 82, Note 1.2 of section 3.2.5 of the Registration Document located at: https://www.ipsen.com/websites/Ipsen_Online/wp-content/uploads/2023/04/06183729/EN_UNIVERSAL-REGISTRATION-DOCUMENT-2022-BD.pdf 17746.00 16585.00 2020 15500.00 None The information provided in response to 22 CCR § 96070(b)(6) is based upon patents listed in the FDA Orange Book.